Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Editor's Note
The use of SGLT-2 inhibitors has grown over the past couple of years as more information is released about them. Many of you reading this special edition have had great successes with these drugs, and there seems to be more data to show why they are so important. However, when Steve and I reached out in a random survey of practitioners, we found that there were still a large percentage of our readers who have never prescribed in this class before. This month we would like to offer a two part series on how to determine if your patients would be good candidates for SGLT-2 Therapy and how to work this class of drugs into their regimen.
Dave Joffe
Editor-in-chief
Latest News
Most important mediator due to changes in markers of plasma volume.
Subanalysis of CANVAS program shows slower progression of kidney disease, reduction in weight, reduction in A1c and even drop in blood pressure.
Why and when to use this therapy to treat patients who have type 2 diabetes.
Surprise findings for treatment class and appropriate patient selection